Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03405337 · ClinicalTrials.gov registry record
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 160
- Enrollment target
NCT03405337: Completed study, sponsored by Bayer.
NCT03405337 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03405337 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A: 1) patients who have switched from conventional therapy to new FVIII products with an improved PK profile. 2) patients who remain on conventional therapy (who have never switched) but have considered switching, including those patients who switched from conventional therapy to new FVIII products with improved pharmacokinetics and then subsequently "switched back" to conventional replacement therapy. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.
Primary Outcome
These patients/caregivers will participate in an asynchronous online discussion forum consisting of predetermined open ended and close ended questions for a series of 6 consecutive days completing approximately 20 minutes' worth of questions per day.
Interventions
- DRUG FVIII products
- DRUG Conventional FVIII replacement therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2018-06-13 |
What the finished NCT03405337 record still lists
NCT03405337 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which FVIII products is the first listed.
NCT03405337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03405337 about?
NCT03405337 is a clinical study titled "Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies". This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A: 1) patients who have switched from conventional therapy t...
What is the current status of trial NCT03405337?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2018-02-14. Estimated completion is 2018-06-13.
What interventions are being tested in trial NCT03405337?
The interventions under investigation include: FVIII products (DRUG), Conventional FVIII replacement therapies (DRUG).
Who is sponsoring clinical trial NCT03405337?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI